It also gives even more arguments to support that the IgA anti-β2GP1 antibodies are no longer the “Cinderella” (39) and that it is advisable to assess the possibility of including them in the APS classification criteria. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.